Skip to main content
Uncategorized

MicroArt Opens New Offices in Edinburgh

By 21 de February de 2008November 18th, 2020No Comments
< Back to news
 21.02.2008

MicroArt Opens New Offices in Edinburgh

, a medical bioinformatics company located at the Barcelona Science Park, announces the opening of a new subsidiary in the United Kingdom. Plans are set for the new subsidiary to join the science park that the University of Edinburgh is fostering, building on the close collaboration that the company has pursued through various research projects undertaken jointly with national and European partners. At the opening ceremony held at 1.30 pm on Friday, 22 February, at the University of Edinburgh (UE), MicroArt's managing director Magí Lluch was joined by other company representatives, by Dave Robertson, who is the director of the "Centre for Intelligent Systems and their Applications", and by Michael Rovatsos, head of the UE's Agents Group. The speakers presented the results of projects jointly carried out by MicroArt and the university.

As Lluch explained, opening the subsidiary is a logical next step in MicroArt’s relationship with the university. The move will increase the company’s international reach, “working as a catalyst to promote collaborative projects at the European level and in the establishment of international consortia”.

MicroArt is a company that specialises in the development of decision support systems in the medical field to help doctors take decisions regarding the medical diagnosis and treatment of pathologies, such as brain tumours and prostate cancer. Drawing on vast amounts of data gathered through the creation of international networks of hospitals, decision support systems employ artificial intelligence techniques like multi-agent systems. The distributed knowledge is then used to benefit local decision-making. In this respect, MicroArt participates in , the premier network grouping together universities and companies across Europe, engaged in the development and application of this technology.

In future, MicroArt intends to expand its scope of activity, developing systems to diagnose other pathologies as well as offering prognoses on patient evolution and assessing the efficiency of possible treatments according to the clinical and genetic profiles of patients.